According to Wikipedia:

Alexander Theodore “Sasha” Shulgin (June 17, 1925 – June 2, 2014) was an American medicinal chemist, biochemist, organic chemist, pharmacologist, psychopharmacologist, and author. He is credited with introducing MDMA (“ecstasy” or “molly”) to psychologists in the late 1970s for psychopharmaceutical use and for the discovery, synthesis and personal bioassay of over 230 psychoactive compounds for their psychedelic and entactogenic potential. In 1991 and 1997, he and his wife Ann Shulgin authored the books PIHKAL and TIHKAL (standing for Phenethylamines and Tryptamines I Have Known And Loved), which extensively described their work and personal experiences with these two classes of psychoactive drugs.

Shulgin performed seminal work into the descriptive synthesis of many of these compounds. Some of Shulgin’s noteworthy discoveries include compounds of the 2C* family (such as 2C-B) and compounds of the DOx family (such as DOM). Due in part to Shulgin’s extensive work in the field of psychedelic research and the rational drug design of psychedelic drugs, he has since been dubbed the “godfather of psychedelics”.

In February of 2018, I requested FBI records and DEA records on Shulgin. The FBI in FOIA Case 1309368-000 gave a “no records” response, but the DEA released the below files.

Document Archive

 Drug Enforcement Agency (DEA) Files on Alexander Shulgin [237 Pages, 83.9MB]

The post Drug Enforcement Agency (DEA) Files on Alexander Shulgin first appeared on The Black Vault.

The mission of the Drug Enforcement Administration (DEA) is to enforce the controlled substances laws and regulations of the United States and bring to the criminal and civil justice system of the United States, or any other competent jurisdiction, those organizations and principal members of organizations, involved in the growing, manufacture, or distribution of controlled substances appearing in or destined for illicit traffic in the United States; and to recommend and support non-enforcement programs aimed at reducing the availability of illicit controlled substances on the domestic and international markets.

Below, you will find a list of reports created by the DEA. Each one, can be requested under the FOIA.

Report Listings

 “BUL Reports” created 2015-2017 [20 Pages, 6.1MB]

 “DIR Reports” created 2015-2017 [8 Pages, 2.5MB]

The post Drug Enforcement Agency (DEA) Report Listings first appeared on The Black Vault.

According to their website, the mission statement of the Drug Enforcement Agency (DEA) is:

“Enforcing the controlled substances laws and regulations of the United States of America. Bringing to justice organizations – including those with ties to terrorism – and their principal members, who are involved in the growing, manufacture or distribution of controlled substances. Supporting the diligent efforts of the Special Agents who play an essential and exclusive role in contributing to our nation’s war on drugs and terrorism. Working to dismantle drug trafficking organizations, prosecute drug traffickers and destroy the financial infrastructure of these organizations. As the government’s premier federal drug law enforcement agency, this is the mission and objective of the Drug Enforcement Administration (DEA). A mission like no other.”

Below, you will find the released training material for this agency’s FOIA program, as released in April 2017.

Document Archive

 Drug Enforcement Agency (DEA) FOIA Training Material, Released April of 2017 [42 Pages, 8.9MB]

https://documents.theblackvault.com/documents/dea/DEA-FOIA-TrainingMaterial.pdf

The post Drug Enforcement Agency (DEA) FOIA Training Material, Released April of 2017 first appeared on The Black Vault.

Drug traffickers and out-of-state opportunists are exploiting Colorado’s medical marijuana laws. Recent revisions to state law have done little to prevent the
involvement of criminals and individuals who use the law for financial gain.

Currently, convicted criminals and known drug traffickers participate in Colorado’s medical marijuana industry. Moreover, an influx of traffickers and entrepreneurs from other states is seeking to cash in on Colorado’s medical marijuana industry. Investigative and intelligence information reveal a significant volume of Colorado-produced marijuana being diverted to out-of-state marijuana markets where it commands a higher price. This activity is facilitated both by  those directly involved in medical marijuana businesses, as well as illicit brokers who seek “excess” or diverted marijuana to sell to marijuana traffickers.

Background

When Amendment 20, which established the state constitutional right for medicinal marijuana in Colorado, was passed by citizen petition in November 2000, the law dealt with the use and distribution of medical marijuana in a very general fashion. By 2010, Coloradans had witnessed a proliferation in the number of medical marijuana patients, caregivers, commercial dispensaries, sophisticated grow operations, and various associated business ventures such as marijuana brokers and consultants. Vague legislation and loose enforcement combined with an aggressive, profitable industry presents ample opportunity for diversion and exploitation. Colorado’s legislative attempts to address the evolving industry are described in DEA-DEN-DIB-012-12. This document identifies avenues being used by drug traffickers and “ganjapreneurs” exploiting the permissive medical marijuana industry for profit.

Download the Document

 DEA Intelligence Brief: Green Acres is the Place to Be – Drug Traffickers and “Ganjapreneurs” Are Exploiting Colorado’s Medical Marijuana Industry, April 24, 2012 [11 Pages, 2.5MB]

https://documents.theblackvault.com/documents/dea/16-00673-F.pdf

The post DEA Intelligence Brief: Green Acres is the Place to Be – Drug Traffickers and “Ganjapreneurs” Are Exploiting Colorado’s Medical Marijuana Industry, April 24, 2012 first appeared on The Black Vault.

In late October 2013, a 31-year-old British national woman reportedly died as a result of cannabis toxicity.

Although a recent review confirmed the coroner’s findings. the exact cause of death remains unclear and several outside organizations dispute claims that the woman’s death was caused by cannabis toxicity.

Significance

Death from cannabis toxicity is highly unusual and this is only the second documented case of this kind to occur in the United Kingdom (UK). In 2004, a 36-year-old man from Wales also is believed to have died as a result of cannabis toxicity. While the woman’s official cause of death is disputed by several marijuana advocacy groups and other medical experts, the coroner found no evidence of any serious medical condition or natural cause of death and, therefore, concluded that cannabis toxicity was the most likely cause.

Although very few deaths have been attributed to cannabis toxicity, marijuana has a wide range of toxic health effects and is potentially fatal, even when
used in small doses.

For example, studies have shown that marijuana increases the heart rate and blood pressure shortly after use, which can result in cardiac arrest, stroke, and other acute pulmonary or cardiovascular reactions, especially in individuals with pre-existing conditions.

Although increasing cannabis consumption and the introduction of more potent varieties of the drug could result in other health issues, fatal overdoses will likely remain rare.

A greater concern is that users will combine marijuana with other substances and/or drive a vehicle while under the influence of the drug.

DEA Bulletin BUL-089-14 – Cannabis Toxicity Death, March 2014

DEA Bulletin BUL-089-14 – Cannabis Toxicity Death, March 2014 [4 Pages, 1.1MB]

https://documents.theblackvault.com/documents/dea/BUL-089-14.pdf

The post DEA Bulletin BUL-089-14 – Cannabis Toxicity Death, March 2014 first appeared on The Black Vault.

Per the request of ADIC WELCH, the following analysis of the FBI/DEA Joint Narcotics Task Force is set forth:

The Task Force was established in September, 1977 with the stated purpose of effecting “optimum use of the resources of both agencies in order to achieve successful prosecution and neutralization of high level narcotics traffickers who are also members of the organized crime element”. 

The Task Force was established with an FBI Supervisor and nine Bureau Agents plus a DEA Group Supervisor with six Agents. The Task Force has been in operation since that time working out of DEA ‘s New York Regional Office on West 57th Street in Manhattan.

A number of major problems have arisen since the inception of the Task Force and the following is an enumeration of those problems:

I. DIFFERENCES IN INVESTIGATIVE METHODS

Despite public protestations to the contrary, DEA remains an agency geared to the ”buy-bust” operation. Her Agents are evaluated and promoted almost exclusively on the number of arrests made and on the amount of narcotics recovered. Largely as a result of these personnel policies, DEA Agents are not usually interested in long-term investigations since such investigations do not normally lead to large numbers of arrests or large recoveries. It is much easier and much better currently from a career standpoint for DEA Agents to work a number of quick turnover cases where their individual statistics can be high. Because of this the DEA Agents assigned to the Task Force are often impatient with the methodical approach taken by Bureau Agents. On numerous occasions, this impatience has damaged particular investigations.

Federal Bureau of Investigation Documents

 Federal Bureau of Investigation Assumption of Federal Drug Enforcement – A Feasibility Study [267 Pages, 153MB]

 Federal Bureau of Investigation Second Release of Documents  [5 Pages, 3.2MB]

The post Assumption of Responsibilities of Drug Enforcement Administration (DEA) By The FBI – A Feasibility Study – June 21, 1977 first appeared on The Black Vault.